MX2022003044A - Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. - Google Patents

Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Info

Publication number
MX2022003044A
MX2022003044A MX2022003044A MX2022003044A MX2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A MX 2022003044 A MX2022003044 A MX 2022003044A
Authority
MX
Mexico
Prior art keywords
cancer
targeting drug
phospholipid ether
drug vehicles
therapeutic compounds
Prior art date
Application number
MX2022003044A
Other languages
English (en)
Spanish (es)
Inventor
Jarrod Longcor
Anatoly Pinchuk
Randall Hoover
Zhongping Huang
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2022003044A publication Critical patent/MX2022003044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2022003044A 2019-09-12 2020-09-11 Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. MX2022003044A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962899615P 2019-09-12 2019-09-12
US201962899611P 2019-09-12 2019-09-12
US201962899618P 2019-09-12 2019-09-12
US201962946870P 2019-12-11 2019-12-11
US202062956907P 2020-01-03 2020-01-03
US202062956844P 2020-01-03 2020-01-03
PCT/US2020/050459 WO2021050917A1 (en) 2019-09-12 2020-09-11 Phospholipid ether conjugates as cancer-targeting drug vehicles

Publications (1)

Publication Number Publication Date
MX2022003044A true MX2022003044A (es) 2022-06-02

Family

ID=74866023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003044A MX2022003044A (es) 2019-09-12 2020-09-11 Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Country Status (11)

Country Link
US (1) US20230066517A1 (cg-RX-API-DMAC10.html)
EP (1) EP4028018A4 (cg-RX-API-DMAC10.html)
JP (3) JP7749542B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220062363A (cg-RX-API-DMAC10.html)
CN (1) CN114599371A (cg-RX-API-DMAC10.html)
AU (2) AU2020346898B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022004482A2 (cg-RX-API-DMAC10.html)
CA (1) CA3150991A1 (cg-RX-API-DMAC10.html)
IL (1) IL291197A (cg-RX-API-DMAC10.html)
MX (1) MX2022003044A (cg-RX-API-DMAC10.html)
WO (1) WO2021050917A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
KR102973364B1 (ko) * 2019-10-10 2026-06-04 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
CN113816990B (zh) * 2021-03-22 2023-08-22 联宁(苏州)生物制药有限公司 修饰的氨基酸及其在adc中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) * 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
CN109310702A (zh) * 2016-05-20 2019-02-05 芝加哥大学 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒
CN109791152B (zh) * 2016-06-14 2023-03-03 塞勒科塔生物科学公司 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物
WO2019200017A1 (en) * 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Also Published As

Publication number Publication date
AU2020346898A1 (en) 2022-04-07
JP2025138792A (ja) 2025-09-25
JP2022547331A (ja) 2022-11-11
BR112022004482A2 (pt) 2022-05-31
AU2020346898B2 (en) 2026-04-09
CN114599371A (zh) 2022-06-07
JP7749542B2 (ja) 2025-10-06
AU2026204469A1 (en) 2026-06-25
WO2021050917A1 (en) 2021-03-18
IL291197A (en) 2022-05-01
EP4028018A1 (en) 2022-07-20
KR20220062363A (ko) 2022-05-16
JP2025087716A (ja) 2025-06-10
EP4028018A4 (en) 2023-10-11
NZ786360A (en) 2025-12-19
US20230066517A1 (en) 2023-03-02
CA3150991A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MX2025000271A (es) Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
MX2023007162A (es) Macrociclos y sus usos.
CL2020001632A1 (es) Compuestos macrocíclicos para tratar enfermedades.
AR110419A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
ECSP12011943A (es) Antagonistas de espiro-oxindol de mdm2
PE20180394A1 (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
BR112022004482A2 (pt) Conjugados de éter fosfolipídico como veículos de fármacos direcionados ao câncer
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CL2023000061A1 (es) Macrociclos y su uso
MX2024014995A (es) Macrociclos que contienen indazol y su uso
CR20240533A (es) Macrociclos de indazol y su uso
MX2021012449A (es) Metodo para tratar tumores.
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
AR115571A1 (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
DOP2025000274A (es) Inhibidores de egfr para el tratamiento de enfermedades